Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

competition on the Company's generic products, decreased net sales of Megace(R) ES, and lower royalty income.

Revenues for the generic products division during the three month period decreased 36.4% to $92.9 million compared with the same period in 2007 due to competitive pressure, including for fluticasone, ranitidine HCl syrup, cabergoline, and a decline in many of the Company's other products due to pricing pressures as well as lower royalties driven from ondansetron ODT. Partially offsetting the decreases were increased sales of metoprolol resulting from the launch of additional strengths in the third quarter of 2007 and various amoxicillin products. Second quarter 2008 revenue for Strativa decreased to $20.0 million from $21.6 million in the prior year due to decreased net sales of Megace(R) ES.

Par's second quarter gross margin was 22.2% of sales, compared with 33.7% in 2007. This decrease is primarily attributed to increased sales of lower margin metoprolol, lower royalty income, lower sales of higher margin products such as propranolol, and a decline in many of the Company's other generic products due to pricing pressures, tempered by higher relative sales of Megace(R) ES. The gross margin rate for Strativa was 79.3% in the second quarter of 2008 compared with 72.5% in the same period in 2007.

Research and development (R&D) expense increased $1.7 million or 11.8% to $16.0 million in the second quarter of 2008, driven primarily by an increase in on-going development costs associated with the expansion of Par's generic portfolio and includes Strativa's research costs related to the development of Zensana(TM) and an initial payment related to the in-licensing agreement with MonoSol Rx.

Second quarter selling, general and administrative (SG&A) expense increased 7.9% to $36.7 million compared with the second quarter of 2007. The increase was driven by legal fees related to ongoing litigation, including Paragraph IV litigation costs. Th
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... May 23, 2013 Graphite Metallizing ... self-lubricating bushings mounted in stainless steel pillow blocks. ... of GRAPHALLOY with the application and installation versatility ... Pillow Blocks work exceptionally well when submerged ... hostile liquids such as acids, alkalies, hydrocarbons, black ...
(Date:5/23/2013)... 23, 2013  Rahal Letterman Lanigan Racing (RLL) and ... stem cell banking and therapeutics, announced today that StemCyte ... Acorn Stairlifts Indy car driven by James ... the IZOD IndyCar 2013 season.   StemCyte, ... support awareness of umbilical cord blood banking and its ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... , , , ... CRGN ) today reported its financial results for the ... its outstanding convertible debt and reached an agreement in principle, expressed ... lawsuits filed in the State of Connecticut and the State of ...
... PHILADELPHIA, July 30 eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), ... biopharmaceutical, medical device and related industries, announced today results for the second ... all comparative numbers refer to changes from the same period a year ... of the second quarter of 2009 were: , , ...
... , , , ... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: ... 2009, the Company entered into definitive purchase agreements with certain ... including Cato Holding Company, which is the venture capital affiliate ...
Cached Biology Technology:CuraGen Reports Second Quarter 2009 Financial Results 2CuraGen Reports Second Quarter 2009 Financial Results 3CuraGen Reports Second Quarter 2009 Financial Results 4CuraGen Reports Second Quarter 2009 Financial Results 5CuraGen Reports Second Quarter 2009 Financial Results 6CuraGen Reports Second Quarter 2009 Financial Results 7CuraGen Reports Second Quarter 2009 Financial Results 8ERT Reports Second Quarter 2009 Results 2ERT Reports Second Quarter 2009 Results 3ERT Reports Second Quarter 2009 Results 4ERT Reports Second Quarter 2009 Results 5ERT Reports Second Quarter 2009 Results 6ERT Reports Second Quarter 2009 Results 7ERT Reports Second Quarter 2009 Results 8ERT Reports Second Quarter 2009 Results 9ERT Reports Second Quarter 2009 Results 10ERT Reports Second Quarter 2009 Results 11ERT Reports Second Quarter 2009 Results 12Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 2Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 3Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 4Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing 5
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
(Date:5/22/2013)... in a major new effort to educate the public ... people with clean water that looms ahead in the ... in the current edition of Chemical & Engineering ... Society (ACS), the world,s largest scientific society. , Bassam ... L. Schnoor, Ph.D., explain that shortages of reliable supplies ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... -- By creating a unique system of blood vessels ... an implanted device, the longevity and function of these ... led by researchers in the University of Louisville/ Jewish ... early online on August 23, 2010 in the ...
... a single gene can cause several types of developmental ... With support from the National Institutes of Health, ... a new gene scanning technology that cuts the cost ... is going to change the way we approach single-gene ...
... Iowa State University researchers will use grants of ... molecules, test technology that can detect food contamination, design ... with potential to grow the state,s economy. The ... to award 10 competitive grants totaling $942,389 from Iowa ...
Cached Biology News:New technology may prolong the life of implanted devices, from pacemakers to chemotherapy ports 2Gene scan finds link across array of childhood brain disorders 2Gene scan finds link across array of childhood brain disorders 3Iowa State awards grants to develop health, energy and research technologies 2Iowa State awards grants to develop health, energy and research technologies 3Iowa State awards grants to develop health, energy and research technologies 4
...
...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... developed using a protein engineering approach that introduced ... of wild-type DNase I. These changes markedly increase ... result is a versatile enzyme that has a ... to maintain at least 50% of peak activity ...
Biology Products: